[Current status and future direction of the treatment of CRPC (castration resistant prostate cancer)].
A new era of the treatment of prostate cancer has now come in Japan with the approval of several new agents for castration resistant prostate cancer (CRPC), which were delayed by 2-3 years compared to their introduction in Westerns. In addition to those development of new agents, a good news was presented in ASCO 2014 that is a successful phase III trial of chemo-hormonal therapy for hormone naïve (responsive) metastatic prostate cancer (HRPC). We must establish a reasonable treatment strategy for the advanced and high risk prostate cancer.